BioCentury | Apr 21, 2020
Product Development

April 20 Quick Takes: Top-line data for BMS, Idorsia and Ascendis; plus Otsuka-Esperion, Regeneron and more

BMS combo meets in Phase III for malignant pleural mesothelioma Bristol Myers Squibb Co. (NYSE:BMY) said top-line results from the Phase III CheckMate -743 trial showed a combination of anti-PD-1 mAb Opdivo nivolumab and anti-CTLA4...
BioCentury | Jul 31, 2019
Financial News

Alizé seeks to build out company with largest European A round this year

French biotech Alizé Pharma 3 is taking a more ambitious approach than its predecessors, and now has a €67 million ($74.5 million) series A round to fund two endocrine programs through Phase II testing and...
BioCentury | Aug 3, 2018
Clinical News

Amgen's Blincyto among negative CHMP opinions

EMA's CHMP released a handful of negative opinions July 27, including one for Blincyto blinatumomab from Amgen Inc. (NASDAQ:AMGN) and, on re-examination, negative recommendations for Dexxience betrixaban from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) and Eladynos abaloparatide-SC...
BioCentury | Jul 27, 2018
Company News

New Blincyto indication among negative CHMP opinions

EMA's CHMP released a handful of negative opinions Friday, including one for Blincyto blinatumomab from Amgen Inc. (NASDAQ:AMGN) and, on re-examination, negative recommendations for Dexxience betrixaban from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) and Eladynos abaloparatide-SC from...
BioCentury | Jun 29, 2018
Financial News

Tricida, Translate Bio, Forty Seven and Entera price IPOs

Among three well-funded biotechs that priced IPOs, Tricida Inc. (NASDAQ:TCDA) had by far the best first-day performance on June 28, posting a 37% gain, while Translate Bio Inc. (NASDAQ:TBIO) and Forty Seven Inc. (NASDAQ:FTSV) each...
BioCentury | Jun 28, 2018
Financial News

Tricida gains, others dip after upsized IPOs

Among three well-funded biotechs that priced IPOs, Tricida Inc. (NASDAQ:TCDA) had by far the best first-day performance Thursday, posting a 37% gain, while Translate Bio Inc. (NASDAQ:TBIO) and Forty Seven Inc. (NASDAQ:FTSV) each lost ground....
BioCentury | Jun 20, 2018
Company News

Management tracks: Sanofi, NantKwest

Sanofi (Euronext:SAN; NYSE:SNY) hired Jean-Baptiste Chasseloup de Chatillon as EVP and CFO, effective Oct. 1. He was CFO and EVP at automotive company PSA Group (Euronext:UG). Natural killer cell company NantKwest Inc. (NASDAQ:NK) said Chief...
BioCentury | Apr 24, 2018
Distillery Therapeutics

Musculoskeletal

INDICATION: Osteoporosis; musculoskeletal Mouse studies suggest inhibiting S1P lyase could help treat osteoporosis and osteopenia. In an osteoprotegerin (OPG)-knockout mouse model of osteoporosis, a tool compound S1P lyase inhibitor increased trabecular bone volume density and...
BioCentury | Mar 30, 2018
Clinical News

CHMP brushes off Radius osteoporosis treatment

EMA's CHMP recommended against approval of Radius' Eladynos abaloparatide-SC to treat osteoporosis in postmenopausal women at increased risk for fracture. Radius said it plans to request a re-examination. Abaloparatide-SC is a subcutaneous peptide analog of...
BioCentury | Mar 23, 2018
Company News

CHMP rebuffs Portola's betrixaban, Radius' abaloparatide-SC

EMA's CHMP issued negative opinions on Friday for Dexxience betrixaban from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) and Eladynos abaloparatide-SC from Radius Health Inc. (NASDAQ:RDUS). The committee recommended against approval of Dexxience to prevent venous thromboembolism (VTE)...
Items per page:
1 - 10 of 802